+

PE20180395A1 - Formas de dosificacion solidas de palbociclib - Google Patents

Formas de dosificacion solidas de palbociclib

Info

Publication number
PE20180395A1
PE20180395A1 PE2017002507A PE2017002507A PE20180395A1 PE 20180395 A1 PE20180395 A1 PE 20180395A1 PE 2017002507 A PE2017002507 A PE 2017002507A PE 2017002507 A PE2017002507 A PE 2017002507A PE 20180395 A1 PE20180395 A1 PE 20180395A1
Authority
PE
Peru
Prior art keywords
dosage forms
palbociclib
solid dosage
water
solid
Prior art date
Application number
PE2017002507A
Other languages
English (en)
Inventor
Fady Makram Louiz Ibrahim
Matthew Patrick Mullarney
Ravi Mysore Shanker
Barbara Rodriguez Spong
Jian Wang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56092955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180395(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PE20180395A1 publication Critical patent/PE20180395A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Formas de dosificacion solidas de palbociclib que comprenden un acido hidrosoluble. Las formas de dosificacion tienen caracteristicas farmacocineticas deseadas.
PE2017002507A 2015-06-04 2016-05-24 Formas de dosificacion solidas de palbociclib PE20180395A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562171177P 2015-06-04 2015-06-04
US201662332973P 2016-05-06 2016-05-06

Publications (1)

Publication Number Publication Date
PE20180395A1 true PE20180395A1 (es) 2018-02-28

Family

ID=56092955

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002507A PE20180395A1 (es) 2015-06-04 2016-05-24 Formas de dosificacion solidas de palbociclib

Country Status (31)

Country Link
US (2) US11065250B2 (es)
EP (2) EP3302565B1 (es)
JP (3) JP2017002034A (es)
KR (2) KR102068423B1 (es)
CN (2) CN107666914A (es)
AU (2) AU2016272881C1 (es)
BR (1) BR112017025398A2 (es)
CA (1) CA2931892A1 (es)
CL (1) CL2017003089A1 (es)
CO (1) CO2017012362A2 (es)
CR (1) CR20170540A (es)
CY (1) CY1122454T1 (es)
DK (1) DK3302565T3 (es)
DO (1) DOP2017000280A (es)
ES (1) ES2764459T3 (es)
HK (1) HK1250570A1 (es)
HR (1) HRP20192065T1 (es)
HU (1) HUE047477T2 (es)
IL (2) IL255632A (es)
LT (1) LT3302565T (es)
MX (2) MX376083B (es)
PE (1) PE20180395A1 (es)
PL (1) PL3302565T3 (es)
PT (1) PT3302565T (es)
RS (1) RS59672B1 (es)
RU (1) RU2686840C1 (es)
SA (1) SA517390473B1 (es)
SI (1) SI3302565T1 (es)
TW (2) TWI635863B (es)
WO (1) WO2016193860A1 (es)
ZA (1) ZA201707780B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400116T1 (it) 2008-10-02 2024-05-14 Salix Pharmaceuticals Ltd Trattamento dell’encefalopatia epatica utilizzando rifaximina
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
WO2017115315A1 (en) * 2015-12-30 2017-07-06 Dr. Reddy's Laboratories Limited Solid forms of palbociclib
CN105816437B (zh) * 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
US10449195B2 (en) * 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN108210454A (zh) * 2016-12-14 2018-06-29 深圳市华力康生物医药有限公司 一种帕布昔利布的口服乳剂及其制备方法
WO2018136596A1 (en) * 2017-01-20 2018-07-26 Constellation Pharmaceuticals, Inc. Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
JP7323451B2 (ja) * 2017-03-08 2023-08-08 シンリックス ファーマ、エルエルシー フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤
CN110573183A (zh) * 2017-04-21 2019-12-13 上海方楠生物科技有限公司 一种帕博西林组合物及其制备方法
WO2018219982A1 (en) * 2017-05-31 2018-12-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
CN106970177B (zh) * 2017-06-06 2018-05-15 北京元延医药科技股份有限公司 帕博西尼中间体及其杂质的分析检测方法
ES2921931T3 (es) 2017-07-10 2022-09-02 Takeda Pharmaceuticals Co Preparación que comprende vonoprazán
WO2019020715A1 (en) * 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING PALBOCICLIB
CN110997666A (zh) * 2017-09-19 2020-04-10 浙江华海药业股份有限公司 N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法
CA3080197C (en) * 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
CN108014343A (zh) * 2017-12-21 2018-05-11 孟斯琴 一种治疗乳腺癌的药物组合物及其制备方法
CN108066303A (zh) * 2017-12-31 2018-05-25 湖南博隽生物医药有限公司 一种抗癌药物组合物及其制备方法
CA3092003A1 (en) 2018-02-27 2019-09-06 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
US11911383B2 (en) 2018-05-14 2024-02-27 Pfizer Inc. Oral solution formulation
WO2019218958A1 (zh) * 2018-05-15 2019-11-21 江苏豪森药业集团有限公司 包含小分子egfr抑制剂的药物组合物及其制备方法
CN108653222A (zh) * 2018-07-03 2018-10-16 威海贯标信息科技有限公司 一种帕博西尼片剂组合物
CN109575021B (zh) * 2019-01-22 2020-09-18 北京海美桐医药科技有限公司 一种哌柏西利的制备方法
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
MA55621A (fr) * 2019-04-11 2022-02-16 Goldfinch Bio Inc Formulation séchée par pulvérisation d'un inhibiteur de pyridazinone trpc5
JP7657222B2 (ja) 2019-12-16 2025-04-04 ルネラ・バイオテック・インコーポレーテッド 選択的ｃｄｋ４／６阻害剤のがん治療薬
IL293940A (en) 2019-12-16 2022-08-01 Lunella Biotech Inc Selective cdk4/6 inhibitor cancer therapeutics
AU2021291437B2 (en) * 2020-06-19 2024-07-04 Acerta Pharma B.V. Acalabrutinib maleate dosage forms
JP7149449B2 (ja) * 2020-07-02 2022-10-06 ＡＲＴｈａｍ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 経口用医薬組成物及びその製造方法
CA3189632A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Combination therapy
CN114246872B (zh) * 2020-09-24 2024-02-06 南京济群医药科技股份有限公司 一种改善羟乙磺酸哌柏西利流动性的工艺方法及组合物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
EP4302755A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024258856A1 (en) * 2023-06-12 2024-12-19 Arvinas Operations, Inc. Solid oral dosage forms of estrogen receptor degraders
KR20250048897A (ko) 2023-10-04 2025-04-11 삼진제약주식회사 용해도 및 안정성이 개선된 팔보시클립을 포함하는 약학 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
EP0946554A1 (en) 1996-11-27 1999-10-06 Pfizer Inc. Fused bicyclic pyrimidine derivatives
EA007395B3 (ru) 2002-01-22 2018-02-28 Уорнер-Ламберт Компани Ллс 2-(ПИРИДИН-2-ИЛАМИНО)ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНЫ
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CA2532049C (en) 2003-07-11 2010-07-20 Warner-Lambert Company Llc Isethionate salt of a selective cdk4 inhibitor
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
MX2008002492A (es) * 2005-08-22 2008-04-03 Novartis Ag Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
CA2640382C (en) 2006-01-27 2015-12-29 Eurand, Inc Drug delivery systems comprising weakly basic drugs and organic acids
MX2009002069A (es) 2006-09-08 2009-03-06 Pfizer Prod Inc Sintesis de 2-(piridin-2-ilamino)pirido[2,3-d]pirimidin-7-onas.
SI2074122T1 (sl) 2006-09-15 2011-10-28 Pfizer Prod Inc Pirido (2,3-d)pirimidinonske spojine in njihova uporaba kot zaviralci PI3
CA2772127A1 (en) * 2009-09-30 2011-04-07 Merck Sharp & Dohme Ltd Formulations for c-met kinase inhibitors
EP2579855B1 (en) 2010-06-09 2014-09-03 AbbVie Bahamas Ltd. Solid dispersions containing kinase inhibitors
CN105708819B (zh) 2011-11-23 2020-12-29 诺华股份有限公司 医药制剂
EP2793864A1 (en) 2011-12-22 2014-10-29 Boehringer Ingelheim International GmbH Immediate release multi unit pellet system
DK3431475T3 (da) 2013-02-21 2021-05-25 Pfizer Faste former af en selektiv CDK4/6-hæmmer
BR112016002465B1 (pt) * 2013-08-14 2022-09-20 Novartis Ag Combinação farmacêutica e seu uso
US20150140036A1 (en) 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN105816437B (zh) 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法

Also Published As

Publication number Publication date
RU2686840C1 (ru) 2019-05-06
SI3302565T1 (sl) 2020-02-28
CL2017003089A1 (es) 2018-05-11
MX2017015579A (es) 2018-03-27
CN107666914A (zh) 2018-02-06
JP2017002034A (ja) 2017-01-05
SA517390473B1 (ar) 2022-12-11
AU2016272881A1 (en) 2017-12-07
EP3636283A1 (en) 2020-04-15
NZ737391A (en) 2023-11-24
ZA201707780B (en) 2020-05-27
HUE047477T2 (hu) 2020-04-28
DOP2017000280A (es) 2018-01-15
HRP20192065T1 (hr) 2020-02-21
RS59672B1 (sr) 2020-01-31
EP3302565A1 (en) 2018-04-11
AU2019204689B2 (en) 2020-12-03
AU2019204689A1 (en) 2019-07-18
TWI635863B (zh) 2018-09-21
TWI763881B (zh) 2022-05-11
ES2764459T3 (es) 2020-06-03
MX376083B (es) 2025-03-07
DK3302565T3 (da) 2020-01-02
EP3302565B1 (en) 2019-11-06
CN113616606A (zh) 2021-11-09
KR20180015232A (ko) 2018-02-12
US20210315900A1 (en) 2021-10-14
IL255632A (en) 2018-01-31
US20180207100A1 (en) 2018-07-26
JP2023112149A (ja) 2023-08-10
BR112017025398A2 (pt) 2018-08-07
US11065250B2 (en) 2021-07-20
CR20170540A (es) 2018-02-02
JP2021167343A (ja) 2021-10-21
AU2016272881C1 (en) 2019-10-03
KR102369405B1 (ko) 2022-03-02
CY1122454T1 (el) 2021-01-27
IL287437A (en) 2021-12-01
KR20200006633A (ko) 2020-01-20
TW201906611A (zh) 2019-02-16
WO2016193860A1 (en) 2016-12-08
MX2020003825A (es) 2020-08-06
CA2931892A1 (en) 2016-12-04
JP7627302B2 (ja) 2025-02-05
LT3302565T (lt) 2019-12-27
PL3302565T3 (pl) 2020-06-01
KR102068423B1 (ko) 2020-01-20
TW201711687A (zh) 2017-04-01
HK1250570A1 (zh) 2018-12-28
CO2017012362A2 (es) 2018-03-28
PT3302565T (pt) 2020-01-14
AU2016272881B2 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
PE20180395A1 (es) Formas de dosificacion solidas de palbociclib
EP3337502A4 (en) STABLE ANTI-IFNAR1 FORMULATION
DK3295582T3 (da) Stråleformning
KR102494289B9 (ko) 활성 혼합물
UA32259S (uk) Розприскувач
DK3277660T3 (da) Vandopløselige L-DOPA-estere
BR112017019826A2 (pt) terminal
CL2018001733A1 (es) Analogos cortistatinos y usos relacionados.
EP3383371A4 (en) PHARMACEUTICAL FORMULATION
PL3226888T3 (pl) Podawanie selektywnego transsygnałowego inhibitora IL-6
DK3316856T3 (da) Blandede formuleringer
EP3600279A4 (en) 1-amino-1-cyclopropanecaboxylic acid formulations
BR112016025075A2 (pt) formulação agroquímica.
ES1171308Y (es) Cuadra Transportable
EP3395344A4 (en) MEDICINE
IL269169A (en) Novel dosage form
DK3288967T3 (da) Farmaceutisk forbindelse
ECSP17085737A (es) Formas de dosificación sólidas de palbociclib
CL2016003220A1 (es) Formulaciones intravaginales que comprenden gnrh.
EP3610781C0 (en) DETERMINATION OF PRESCRIPTIONS
UA36871S (uk) Печиво
UA37342S (uk) Печиво
UA36079S (uk) Печиво
UA35720S (uk) Печиво
IT201700103032A1 (it) Moschettone
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载